PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'London School of Hygiene & Tropical Medicine, London, UK deborah.Watson-Jones@lshtm.ac.uk.\', \'Mwanza Intervention Trials Unit, Mwanza, Tanzania, United Republic of.\', \'L\'Institut National de Recherche Biomédicale, Goma, Democratic Republic of the Congo.\', \'Epicentre, Paris, Île-de-France, France.\', \'MSF, Paris, France.\', \'London School of Hygiene & Tropical Medicine, London, UK.\', \'Janssen Vaccines and Prevention BV, Leiden, Zuid-Holland, The Netherlands.\', \'Coalition for Epidemic Preparedness Innovations, Oslo, Norway.\', \'UK Public Health Rapid Support Team, Public Health England and LSHTM, London, UK.\', \'L\'Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1136/bmjopen-2021-055596
?:hasPublicationType
?:journal
  • BMJ open
is ?:pmid of
?:pmid
?:pmid
  • 35260458
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.372
?:rankingScore_hIndex
  • 57
?:title
  • Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35260458>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35260458>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all